Technical Analysis for PFE - Pfizer, Inc.

Grade Last Price % Change Price Change
F 24.83 -0.45% -0.11
PFE closed down 0.64 percent on Wednesday, November 20, 2024, on 1.18 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
60 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction -0.45%
NR7 Range Contraction -0.45%
Lower Bollinger Band Walk Weakness -0.45%
Inside Day Range Contraction -0.45%
Oversold Stochastic Weakness -0.45%
Lower Bollinger Band Walk Weakness -1.08%
Gapped Down Weakness -1.08%
Lower Bollinger Band Touch Weakness -1.08%
Oversold Stochastic Weakness -1.08%
Jack-in-the-Box Bearish Bearish Swing Setup -0.13%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 20 hours ago
Possible Inside Day about 20 hours ago
Lower Bollinger Band Support about 22 hours ago
60 Minute Opening Range Breakdown about 22 hours ago
Down 1% about 24 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pfizer, Inc. Description

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care physicians for Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation therapeutic and disease areas. The company's Specialty Care and Oncology segment provides human prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. Its Established Products and Emerging Markets segment offers human prescription pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions, as well as that are sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. The company's Animal Health segment offers products and services to prevent and treat disease in livestock and companion animals, including anti-infectives, vaccines, parasiticides, medicinal feed additives, other pharmaceutical products, and other non-pharmaceutical products. Its Consumer Healthcare segment provides non-prescription products in therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. has a strategic collaboration with CytomX Therapeutics, Inc. to develop and commercialize Multiple Probody drug conjugates in oncology. The company was founded in 1849 and is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Biopharmaceutical Disease Pain Medication Clinic Pharmaceutical Products Neuroscience Inflammation Alzheimer's Disease Hypertension Ophthalmology Animal Health Dietary Supplement Pain Management Dysfunction Major Depressive Disorder Depressive Disorder Pulmonary Arterial Hypertension Smoking Primary Care Hemophilia Smoking Cessation Anti Infectives Endocrine Disorders Erectile Dysfunction Livestock Producers Prescription Product Prescription Products Genitourinary

Is PFE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.0576
52 Week Low 24.1057
Average Volume 39,061,081
200-Day Moving Average 27.36
50-Day Moving Average 28.00
20-Day Moving Average 26.84
10-Day Moving Average 25.86
Average True Range 0.61
RSI (14) 27.54
ADX 35.14
+DI 8.51
-DI 34.94
Chandelier Exit (Long, 3 ATRs) 26.90
Chandelier Exit (Short, 3 ATRs) 26.30
Upper Bollinger Bands 29.18
Lower Bollinger Band 24.49
Percent B (%b) 0.1
BandWidth 17.45
MACD Line -0.89
MACD Signal Line -0.68
MACD Histogram -0.2089
Fundamentals Value
Market Cap 140.82 Billion
Num Shares 5.65 Billion
EPS 0.37
Price-to-Earnings (P/E) Ratio 67.41
Price-to-Sales 2.70
Price-to-Book 1.61
PEG Ratio 1.17
Dividend 1.64
Dividend Yield 6.58%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.62
Resistance 3 (R3) 25.59 25.35 25.50
Resistance 2 (R2) 25.35 25.17 25.36 25.46
Resistance 1 (R1) 25.14 25.07 25.02 25.17 25.43
Pivot Point 24.90 24.90 24.84 24.91 24.90
Support 1 (S1) 24.69 24.72 24.57 24.72 24.45
Support 2 (S2) 24.45 24.62 24.46 24.42
Support 3 (S3) 24.24 24.45 24.38
Support 4 (S4) 24.27